Abstract
The structural determinants of G protein coupling versus activation by G protein-coupled receptors are not well understood. We examine the role of two distinct basic regions in the carboxyl terminal portion of the third intracellular loop of the α2A-adrenergic receptor to dissect these aspects of function. Changing three arginines to alanines by mutagenesis and stable expression in Chinese hamster ovary-K1 cells impaired the α2-adrenergic receptor Gs-mediated stimulation of cyclic AMP (cAMP) accumulation, whereas Gi-mediated inhibition was normal. When two (B2) or three (B3) basic residues closer to transmembrane span 6 were mutated to alanine, normal ligand binding was observed, but Gi-mediated inhibition of cAMP accumulation showed 20-fold and 50-fold decreases in agonist potency for the B2 and B3 mutants, respectively. Surprisingly, a normal Gs response was seen for the B2 mutant, and the B3 mutant showed only a 6-fold decrease in agonist potency. Mutation of both the three alanines and B3 residues to alanines showed a 200-fold decrease in agonist potency for Gi-mediated inhibition of cAMP accumulation, whereas the Gs response was nearly completely eliminated. The three basic residues (which include the BB of the BBXXF motif) play a role as Gi activators rather than in receptor-G protein coupling, because high-affinity agonist binding is intact. Thus, we have identified three basic residues required for activation of Gi but not required for receptor-G protein coupling. Also, distinct basic residues are required for optimal Gi and Gs responses, defining a microspecificity determinant within the carboxyl terminal portion of the third intracellular loop of the α2a adrenergic receptor.
Footnotes
- Received April 20, 1999.
- Accepted July 30, 1999.
-
Send reprint requests to: Richard R. Neubig, M.D., Ph.D., Department of Pharmacology, 1301 MSRB III, 1150 W. Medical Center Dr, Ann Arbor, MI 48109-0632. E-mail:rneubig{at}umich.edu
-
This work was supported by National Institutes of Health Grant HL46417, the University of Michigan Multipurpose Arthritis Center (AR20557), and Natural Sciences and Engineering Research Council of Canada APP 207830-1998 (D.A.C.).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|